These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 33784797

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H, Will S, Guionaud S, Boland ML, Oldham S, Ravn P, Celeste A, Trevaskis JL.
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [Abstract] [Full Text] [Related]

  • 3. Soyasaponin A2 Alleviates Steatohepatitis Possibly through Regulating Bile Acids and Gut Microbiota in the Methionine and Choline-Deficient (MCD) Diet-induced Nonalcoholic Steatohepatitis (NASH) Mice.
    Xiong F, Zheng Z, Xiao L, Su C, Chen J, Gu X, Tang J, Zhao Y, Luo H, Zha L.
    Mol Nutr Food Res; 2021 Jul; 65(14):e2100067. PubMed ID: 34047448
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW, Lynch KD.
    Br Med Bull; 2020 May 15; 133(1):95-104. PubMed ID: 32282030
    [Abstract] [Full Text] [Related]

  • 6. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
    Goto T, Itoh M, Suganami T, Kanai S, Shirakawa I, Sakai T, Asakawa M, Yoneyama T, Kai T, Ogawa Y.
    Sci Rep; 2018 May 25; 8(1):8157. PubMed ID: 29802399
    [Abstract] [Full Text] [Related]

  • 7. Alanyl-Glutamine Protects Mice against Methionine- and Choline-Deficient-Diet-Induced Steatohepatitis and Fibrosis by Modulating Oxidative Stress and Inflammation.
    Hu J, Zheng Y, Ying H, Ma H, Li L, Zhao Y.
    Nutrients; 2022 Sep 15; 14(18):. PubMed ID: 36145172
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
    Adorini L, Rigbolt K, Feigh M, Roth J, Erickson M.
    PLoS One; 2024 Sep 15; 19(4):e0300809. PubMed ID: 38662778
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N, Janssen AWF, Milona A, Ramos Pittol JM, Hollman DAA, Mokry M, Betzel B, Berends FJ, Janssen IM, van Mil SWC, Kersten S.
    J Hepatol; 2016 May 15; 64(5):1158-1166. PubMed ID: 26812075
    [Abstract] [Full Text] [Related]

  • 14. A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction.
    An P, Wei G, Huang P, Li W, Qi X, Lin Y, Vaid KA, Wang J, Zhang S, Li Y, Or YS, Jiang LJ, Popov YV.
    Liver Int; 2020 Jul 15; 40(7):1655-1669. PubMed ID: 32329946
    [Abstract] [Full Text] [Related]

  • 15. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.
    Zhou J, Cui S, He Q, Guo Y, Pan X, Zhang P, Huang N, Ge C, Wang G, Gonzalez FJ, Wang H, Hao H.
    Nat Commun; 2020 Jan 13; 11(1):240. PubMed ID: 31932588
    [Abstract] [Full Text] [Related]

  • 16. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A, Biagioli M, Marchianò S, Fiorucci C, Zampella A, Monti MC, Scarpelli P, Ricci P, Distrutti E, Fiorucci S.
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct 13; 1864(10):1422-1437. PubMed ID: 31325638
    [Abstract] [Full Text] [Related]

  • 17. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.
    Rodrigues PM, Afonso MB, Simão AL, Carvalho CC, Trindade A, Duarte A, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CM, Castro RE.
    Cell Death Dis; 2017 Apr 13; 8(4):e2748. PubMed ID: 28406477
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D.
    Gastroenterology; 2013 Sep 13; 145(3):574-82.e1. PubMed ID: 23727264
    [Abstract] [Full Text] [Related]

  • 20. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.
    Wu W, Liu X, Peng X, Xue R, Ji L, Shen X, Chen S, Gu J, Zhang S.
    Biochem Biophys Res Commun; 2014 May 23; 448(1):50-5. PubMed ID: 24747563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.